Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Dupont Merck
- Registration Number
- NCT00002410
- Locations
- 🇺🇸
Bach and Godofsky, Bradenton, Florida, United States
🇺🇸Oasis Clinic / Martin Luther Jr Gen Hosp / King-Drew Med Ctr, Los Angeles, California, United States
🇺🇸Remington-Davis Inc, Columbus, Ohio, United States
A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 600
- Registration Number
- NCT00002155
- Locations
- 🇺🇸
Merck & Co Inc, Whitehouse Station, New Jersey, United States
The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT00002379
- Locations
- 🇺🇸
Phoenix Body Positive, Phoenix, Arizona, United States
🇺🇸Saint Vincent's AIDS Ctr, New York, New York, United States
🇺🇸George Washington Med Ctr, Washington, District of Columbia, United States
A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 290
- Registration Number
- NCT00002195
- Locations
- 🇺🇸
Chicago Ctr for Clinical Research, Chicago, Illinois, United States
🇺🇸Dr Bruce Rashbaum, Washington, District of Columbia, United States
🇺🇸Community Research Initiative of South Florida, Coral Gables, Florida, United States
A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 230
- Registration Number
- NCT00005106
- Locations
- 🇺🇸
Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸THE Clinic, Los Angeles, California, United States
🇺🇸Maxine Liggins, Los Angeles, California, United States
A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002442
- Locations
- 🇺🇸
Southwest Infectious Disease Association / PA, Dallas, Texas, United States
🇺🇸Univ TX Galveston Med Branch, Galveston, Texas, United States
🇺🇸St Lukes - Roosevelt Hosp Ctr, New York, New York, United States
A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia and Upjohn
- Target Recruit Count
- 45
- Registration Number
- NCT00002400
- Locations
- 🇺🇸
Pharmacia & Upjohn, Peapack, New Jersey, United States
Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Agouron Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT00005000
- Locations
- 🇺🇸
Agouron Pharmaceuticals Inc, San Diego, California, United States
A Study of Two Anti-HIV Drug Combinations
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002203
- Locations
- 🇺🇸
Carolinas Med Ctr, Charlotte, North Carolina, United States
🇺🇸Univ of North Carolina Hosps, Chapel Hill, North Carolina, United States
🇺🇸Pacific Oaks Med Ctr, Beverly Hills, California, United States
Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00004852
- Locations
- 🇺🇸
Univ of Texas / Med School at Houston, Houston, Texas, United States
🇺🇸Harbor - UCLA Med Ctr, Torrance, California, United States
🇺🇸Bach and Godofsky, Bradenton, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.